BioCatalystWatch
GDTCWorkspace / GDTC / OverviewCompany library

CytoMed Therapeutics Limited

CytoMed Therapeutics Limited (GDTC)

Price
Market cap
Next catalystExpected Q1 2027CTM-GDT — planned Malaysian first-in-human trial · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

CTM-N2D

Cell therapy

NKG2D ligands (ULBP1-6, MICA/B)

PreINDP1P2P3FilingApproved
CTM-N2D

Cell therapy

NKG2D ligands (ULBP1-6, MICA/B)

PreINDP1P2P3FilingApproved
Upcoming / outlook

CTM-GDT

Cell therapy

PreINDP2P3FilingApproved
Upcoming / outlook

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

GDTC PR & News

PR & News

GDTC SEC archive